Samuele Doratori

Head Cardiometabolic&Venous Diseases - Global Product Strategy -Servier. Contents shared don’t necessarily represent Servier view

[Samuele Doratori @SamueleDorator1]

CV disease constitutes an economic burden, often underestimated. Just released data in EU: €282 billion estimated annual cost (productivity losses amounts to 17%➡️€48 billion). On average, CVD costs €630 per person #EHJ https://t.co/8QiNzcNhY8…
#ESCCongress #ESC2023

[Samuele Doratori @SamueleDorator1]

The essence of INNOVATION lies in OPTIMISING THE USE OF THE ALREADY AVAILABLE THERAPIES and IMPROVING PATIENT UNDERSTANDING,

as its complexity requires MULTIPLE TREATMENTS FOR MULTIPLE CARDIOMETABOLIC CONDITIONS

[Samuele Doratori @SamueleDorator1]

WHAT THIS IMAGE IS NOT:
▪️a meeting room
▪️ a presentation of new study or drug.
It shows people sitting on the floor outside a crowded hall at the #ESC2023 ( #ESCcongress ) during a session on CV diseases management

#adherence #cardiometabolic #esc

[Samuele Doratori @SamueleDorator1]

I share my new position as Head of CardioMetabolic&Venous Diseases at the Global Product Strategy at @Servier
The upcoming #ESCCongress in Amsterdam presents a prime chance to unveil our new organization to colleagues from affiliates.
#Cardiometabolic #ESC2023 #cardiovascular

[Samuele Doratori @SamueleDorator1]

🌐 WHO’s latest update:
Fixed-dose combinations now on the essential medicine list to boost adherence and prevent cardiovascular diseases.
Will it be a game changer? Let’s discuss it during the next #ESCCongress

#who #adherence #FDCs #cardiovascular #ESC https://t.co/ErNG4vufiE

[Samuele Doratori @SamueleDorator1]

Another step in understanding healthcare system dynamics.

Ultimately, it’s all around value “creation & capture” and its impact on advancing healthcare effectiveness

#healthcare #strategy

Harvard Business School

[Samuele Doratori @SamueleDorator1]

1Day of the ESH Congress. The challenges in hypertension are centered on better patients understanding:
✅ Ethnic and genetic differences,
✅ Tailored treatments for comorbidities,
✅ Enhancing control & adherence through therapeutic Innovation, digital solutions and education

[Medscape @Medscape]

In patients with gliomas bearing IDH1/2 mutations, the brain barrier-crossing oral drug vorasidenib kept tumors at bay, and could be used instead of more toxic chemotherapies and radiation. #ASCO23 https://t.co/yLmMaMG8In

[Ben Fulcher @bendfulcher]

No one is talking about how amazing Photoshop's generative AI is going to be for science. A simple "improve correlation" prompt and say goodbye to p > 0.05!

[Samuele Doratori @SamueleDorator1]

Simple and inspiring “article & algorithm” that could shape the future of chronic disease management.
One of the main challenge in healthcare is the improvement of outcomes/adherence (interconnected goals) in patients with cardiometabolic comorbidities https://t.co/z8Mabrqi6E

[Institut Sapiens @Instit_Sapiens]

🩺 On estime que 90 % des patients ne suivent pas les instructions thérapeutiques à la lettre.

“ Pour remédier à la non-adhésion #thérapeutique, 3 solutions :

- l’éducation des #patients et la formation des #médecins
- le numérique
- les combinaisons fixes ”

@SamueleDorator1 nous apporte son expertise pour lutter contre ce fléau.

#nonadhesion #traitement #médicaments

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

Dr. Fuster explaining that the normal LDL for an adult should be <70, SBP<120mmg and Hgb A1C<5.7%. He plans to study this in a RCT, see design here. #ACC23

[Samuele Doratori @SamueleDorator1]

#CVCT2022 #CardioTwitter #Cardiology here we start. Exchanging perspectives around Fixed (flexible?) dose combinations and polypills across the cardiometabolic continuum..

[Samuele Doratori @SamueleDorator1]

@CVCTForum #CardioTwitter here we start. Fixed dose combinations and polypills across the cardiometabolic continuum. Exchanging perspectives..

[Samuele Doratori @SamueleDorator1]

@kamleshkhunti @YoginiChudasama @NIHRCRNEastMids @mmamas1973 @AnastasiaSMihai @AskDrShashank @AmarPut @AliRacaniere @docwas @rcgp Bad news

[Samuele Doratori @SamueleDorator1]

Can2simple images sum-up the biggest challenge to the number 1 cause mortality?
Reducing the implementation GAP of evidences is possible by associating:
-education (doctors/patients) 👥
-beyond the pill🤳🏽
-combining the most effective, proven and available drugs💊to ⬆️ adherence

[Samuele Doratori @SamueleDorator1]

‘Polypill could avoid millions of premature deaths, heart attacks and strokes’ | The Independent https://t.co/xDVbjeSEIA

[Samuele Doratori @SamueleDorator1]

@kamleshkhunti @SouthAsianHF @docwas @parthaskar @drpatrickholmes @NHSEngland @NIHRresearch @ARC_EM @ERobertson02 @AliRacaniere @ShivaniM_KC @ABCDiab “Multimorbidity as major future challenge” (why not the present one?)